IGFBP7 and COVID-19: Patients with COVID-19 AKI and high levels of tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein-7 [TIMP-2] × [IGFBP-7] were more likely to progress to RRT than patients with AKI but with low [TIMP-2] × [IGFBP-7]64.